The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| APS | -70.9% | -99.91% | -75.17% | -100% |
| S&P | +12.65% | +84.17% | +12.99% | +1,415% |
Aptose Biosciences, Inc. is a clinical-stage oncology company, which engages in the discovery, research, and development of anti-cancer therapies. Its product pipeline includes APTO-253, a small molecule that induces expression of the Kruppel-Like Factor 4 genes; and CG-806 a non-covalent small molecule therapeutic agent. The company was founded on September 5, 1986 and is headquartered in Toronto, Canada.
No news articles found for Aptose Biosciences.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | -$152.88K | -16.8% |
| Market Cap | $4.19M | -59.5% |
| Market Cap / Employee | $322.00K | 0.0% |
| Employees | 13 | -62.9% |
| Net Income | -$7,056.00K | 25.6% |
| EBITDA | -$6,613.88K | 29.4% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $2.28M | -78.8% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $26.04M | 87.0% |
| Short Term Debt | $424.38K | -24.5% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -228.70% | -2.2% |
| Return On Invested Capital | 326.37% | -79.8% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$10,267.45K | 27.2% |
| Operating Free Cash Flow | -$10,267.45K | 27.2% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | -2.99 | -1.40 | -0.28 | -0.21 | -74.54% |
| Price to Tangible Book Value | -15.42 | -1.40 | -0.28 | -0.21 | -99.78% |
| Enterprise Value to EBITDA | -8.63 | -2.05 | -1.77 | -4.29 | 196.27% |
| Return on Equity | -292.1% | -359.8% | -714.8% | - | |
| Total Debt | $15.30M | $12.93M | $15.52M | $26.46M | 82.69% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
